Akums Drugs & Pharmaceuticals Ltd (AKUMS) — shareholding pattern, promoter holding, financials and share price
About Akums Drugs & Pharmaceuticals Ltd (AKUMS)
Akums Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AKUMS and on the BSE under scrip code 544222. Its ISIN is INE09XN01023.
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]
Akums Drugs and Pharmaceuticals Limited is an integrated pharmaceutical CDMO and formulations company that manufactures finished dosage forms, sterile injectables and APIs while also marketing branded formulations through its Akumentis business; the company combines domestic branded sales with a CDMO focus, exports and an API vertical across multiple accredited manufacturing sites.
Q3 FY26 showed strong operating momentum for Akums: consolidated total income of INR1,194 crore (+16.5% YoY), operating revenue of INR1,160 crore (+14.8% YoY), Adj. EBITDA of INR147 crore (12.7% margin, +21% YoY) and CDMO contributing roughly 79% of revenues, reflecting successful volume-led growth despite API price pressure.
Listed peers in Pharmaceuticals: Shilpa Medicare Ltd, Viyash Scientific Ltd, Procter & Gamble Health Ltd, Blue Jet Healthcare Ltd, Sanofi Consumer Healthcare India Ltd, Strides Pharma Science Ltd.
Valuation & Returns
10 Jul 2026At ₹704.5 a share on 10 Jul 2026, Akums Drugs & Pharmaceuticals Ltd (AKUMS) was valued at a price-to-earnings ratio of 43.25x against an industry P/E of 36.41x and a price-to-book of 3.35x on a book value of ₹210.51 per share as of Mar 2026. Solomo computes return on equity of 7.74% and return on capital employed of 13.72% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 43.25x
- Industry P/E
- 36.41x
- P/B
- 3.35x
- EPS (TTM)
- ₹16.29
- Book value / share
- ₹210.51
- ROE
- 7.74%
- ROCE
- 13.72%
- ROA
- 4.71%
- Debt / equity
- 0.05x
- Dividend yield
- 0.14%
- EBITDA margin
- 14.47%
- 52-week range
- ₹410.1 – ₹707
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Akums Drugs & Pharmaceuticals Ltd (AKUMS) reported revenue of ₹4,359 crore, net profit of ₹256 crore and earnings per share of ₹16.21. That compares with revenue of ₹4,118 crore and net profit of ₹344 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,158 crore and net profit ₹81 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 |
| Net profit (₹ cr) | -251 | 98 | 1 | 344 | 256 |
| EPS (₹) | -35.3 | 6.63 | -0.28 | 21.49 | 16.21 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 10.02% | 1.58% | 5.85% |
| Profit growth | - | -3.81% | -25.42% |
| Stock price CAGR | - | - | 22% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 75.26% of Akums Drugs & Pharmaceuticals Ltd (AKUMS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.91% and domestic institutional investors (DII) hold 13.44%. Market capitalisation was ₹11,088 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Jun 2026: Franklin India Opportunites Fund 4.19%, Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 3.14%, Clarus Capital I 2.17%, Bandhan Small Cap Fund 1.13%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 75.26% | - | 1.91% | 13.44% | 22.01% |
| Mar 2026 | 75.26% | - | 1.37% | 14.35% | 22.01% |
| Dec 2025 | 75.26% | - | 1.15% | 14.4% | 22.01% |
| Sep 2025 | 75.26% | - | 2.28% | 9.28% | 22.01% |
| Jun 2025 | 75.26% | - | 4.24% | 8.85% | 22.01% |
| Mar 2025 | 75.26% | - | 5.77% | 7.4% | 22.01% |
| Dec 2024 | 75.26% | - | 6.36% | 7% | 22.01% |
| Sep 2024 | 75.26% | - | 7.34% | 7.52% | 22.01% |